Media Statement on Reproductive Health Medication Access

As a pharmaceutical distributor, AmerisourceBergen’s role is to provide logistical connectivity between pharmaceutical manufacturers and their FDA approved products and healthcare providers – including hospitals, physician offices and other sites of care – while complying with all applicable laws and regulations. 

We have and will continue to make Mifeprex available to eligible medical providers in all 50 states, and with the January 2023 FDA decision to allow retail pharmacies to dispense Mifeprex, we are distributing to certified retail sites of care in states where it is consistent with the law.

AmerisourceBergen does not and should not make clinical decisions or values-based judgements on which FDA approved products it distributes. If AmerisourceBergen – a non-clinical entity – were to act based on values-based judgements regarding which FDA approved products we distribute, we would be superseding the clinical judgments of healthcare providers, as well as the decisions made by regulators and health authorities, on which products should be available to the American population. Our role as a distributor is to create efficient and safe access to FDA approved medication, and it is not to independently decide what medications should be available to health care professionals as part of their treatment plans.